Single probe brightfield ISH is a robust and reproducible technique for the assessment of HER2 status in breast cancer.

被引：0
|
作者：
Di Palma, S. [1 ]
Collins, N. [1 ]
Mottolese, M. [1 ]
Schmitt, F. [1 ]
Sapino, A. [1 ]
Kapranos, N. [1 ]
Boecker, W. [1 ]
Bilous, M. [1 ]
Isola, J. [1 ]
机构：
[1] Univ Turin, Turin, Italy
来源：
VIRCHOWS ARCHIV | 2007年 / 451卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：304 / 305
页数：2
相关论文
共 50 条
  • [1] HER2 Dual ISH Determination of HER2 Gene Status in Breast Cancer: Interobserver Reproducibility
    Limbach, A. A. Lott
    Downs-Kelly, E. P.
    Papouchado, B. G.
    Tubbs, R. R.
    Lanigan, C.
    Booth, C. N.
    LABORATORY INVESTIGATION, 2012, 92 : 52A - 52A
  • [2] HER2 Dual ISH Determination of HER2 Gene Status in Breast Cancer: Interobserver Reproducibility
    Limbach, A. A. Lott
    Downs-Kelly, E. P.
    Papouchado, B. G.
    Tubbs, R. R.
    Lanigan, C.
    Booth, C. N.
    MODERN PATHOLOGY, 2012, 25 : 52A - 52A
  • [3] Assessment of HER2 status in breast cancer
    Penault-Llorca, F
    Cayre, A
    BULLETIN DU CANCER, 2004, 91 : S211 - S215
  • [4] Quantification of intratumoral heterogeneity of HER2 status in breast cancer.
    Horii, Rie
    Matsuura, Masaaki
    Nitta, Hiro
    Ito, Yoshinori
    Ohno, Shinji
    Iwase, Takuji
    Akiyama, Futoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Her2/neu status in locally advanced breast cancer.
    Doran, CM
    Cameron, DA
    Watters, AD
    Leonard, RCF
    Bartlett, JMS
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 278 - 278
  • [6] Automatization of HER2 Status Assessment in Breast Cancer
    Makhov, Denis
    Samorodov, Andrey
    Slavnova, Elena
    2019 URAL SYMPOSIUM ON BIOMEDICAL ENGINEERING, RADIOELECTRONICS AND INFORMATION TECHNOLOGY (USBEREIT), 2019, : 171 - 173
  • [7] Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry
    Hicks, David G.
    LABMEDICINE, 2011, 42 (08): : 459 - 467
  • [8] Neoadjuvant Treatment in Breast Cancer; Relationship to HER2 status including HER2 Copy Number using Brightfield Dual in situ Hybridization
    Neville, Grace
    O'Connell, Fionnuala
    Bennett, Michael
    Feeley, Linda
    O'Reilly, Seamus
    Browne, Tara Jane
    LABORATORY INVESTIGATION, 2018, 98 : 95 - 95
  • [9] Neoadjuvant Treatment in Breast Cancer; Relationship to HER2 status including HER2 Copy Number using Brightfield Dual in situ Hybridization
    Neville, Grace
    O'Connell, Fionnuala
    Bennett, Michael
    Feeley, Linda
    O'Reilly, Seamus
    Browne, Tara Jane
    MODERN PATHOLOGY, 2018, 31 : 95 - 95
  • [10] HER2 overexpressing metastatic breast cancer.
    Spigel D.R.
    Burstein H.J.
    Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
12345